Thanyawee Puthanakit1, Torsak Bunupuradah. 1. Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. thanyawee@hivnat.org
Abstract
PURPOSE OF REVIEW: We reviewed current literatures on early and deferred initiation of antiretroviral therapy in HIV-infected infants and children in low-income and middle-income countries. RECENT FINDINGS: Data from children with HIV antiretroviral (Children with HIV Early Antiretroviral Therapy) study showed a significant reduction of 76% in mortality among infants who received antiretroviral therapy within 3 months of their life as opposed to those on deferred therapy. These data led World Health Organization to promptly revise the guideline to recommend initiation of antiretroviral therapy in all HIV-infected infants regardless of clinical or immunological status. The recommendation for older children is differed between guidelines of developed and developing countries. In general, higher CD4 cell count threshold is used for younger children and similar criteria to those used for adults are used once children are above 5 years of age. The randomized study of when to start antiretroviral therapy in children older than 1 year is ongoing. SUMMARY: The current trend is to move toward early treatment to reduce morbidity and mortality, achieve immune recovery, normal growth, and development. Even though the antiretroviral rollout program has been successful in Asia and Africa, the challenges lie in diagnosing infants in a timely manner and maintaining infrastructure and resources to support life-long treatment.
PURPOSE OF REVIEW: We reviewed current literatures on early and deferred initiation of antiretroviral therapy in HIV-infectedinfants and children in low-income and middle-income countries. RECENT FINDINGS: Data from children with HIV antiretroviral (Children with HIV Early Antiretroviral Therapy) study showed a significant reduction of 76% in mortality among infants who received antiretroviral therapy within 3 months of their life as opposed to those on deferred therapy. These data led World Health Organization to promptly revise the guideline to recommend initiation of antiretroviral therapy in all HIV-infectedinfants regardless of clinical or immunological status. The recommendation for older children is differed between guidelines of developed and developing countries. In general, higher CD4 cell count threshold is used for younger children and similar criteria to those used for adults are used once children are above 5 years of age. The randomized study of when to start antiretroviral therapy in children older than 1 year is ongoing. SUMMARY: The current trend is to move toward early treatment to reduce morbidity and mortality, achieve immune recovery, normal growth, and development. Even though the antiretroviral rollout program has been successful in Asia and Africa, the challenges lie in diagnosing infants in a timely manner and maintaining infrastructure and resources to support life-long treatment.
Authors: Mireille Porter; Mary-Ann Davies; Muntanga K Mapani; Helena Rabie; Sam Phiri; James Nuttall; Lee Fairlie; Karl-Günter Technau; Kathryn Stinson; Robin Wood; Maureen Wellington; Andreas D Haas; Janet Giddy; Frank Tanser; Brian Eley Journal: J Acquir Immune Defic Syndr Date: 2015-08-15 Impact factor: 3.731
Authors: Michael Schomaker; Matthias Egger; James Ndirangu; Sam Phiri; Harry Moultrie; Karl Technau; Vivian Cox; Janet Giddy; Cleophas Chimbetete; Robin Wood; Thomas Gsponer; Carolyn Bolton Moore; Helena Rabie; Brian Eley; Lulu Muhe; Martina Penazzato; Shaffiq Essajee; Olivia Keiser; Mary-Ann Davies Journal: PLoS Med Date: 2013-11-19 Impact factor: 11.069
Authors: Jihane Ben-Farhat; Marianne Gale; Elisabeth Szumilin; Suna Balkan; Elisabeth Poulet; Mar Pujades-Rodríguez Journal: Trop Med Int Health Date: 2013-06-20 Impact factor: 2.622